EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer
The validations confirm the completion of the applications and commence the scientific review process
The validations confirm the completion of the applications and commence the scientific review process
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
Transcatheter Mitral valve procedure allows intervention on patients who are unsuitable or high risk for open heart surgery
Subscribe To Our Newsletter & Stay Updated